Education
About Us
Working with TipRanks
Follow Us
Merus NV (MRUS)
NASDAQ:MRUS
MRUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$33.19 - $94.56
Previous CloseN/A
Volume56.75K
Average Volume (3M)2.51M
Market Cap
$7.14B
Enterprise Value$3.04B
Total Cash (Recent Filing)$710.22M
Total Debt (Recent Filing)$11.00M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Oct 30, 2025EPS Estimate
-1.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding75,784,440
10 Day Avg. Volume6,261,742
30 Day Avg. Volume2,507,171
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue54.07
Enterprise Value/Gross Profit54.07
Enterprise Value/Ebitda-7.84
Forecast
1Y Price Target
$97.07Price Target Upside2.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Bulls Say, Bears Say
Bulls Say
Acquisition BenefitsGenmab's acquisition of Merus for $8.0B is a significant positive for shareholders, providing a favorable outcome and removing residual FDA regulatory risk.
Pipeline ExpansionMerus' acquisition will add petosemtamab, a promising oncology asset, to Genmab's growing portfolio, highlighting potential multi-billion dollar peak sales.
Premium AcquisitionMerus is being acquired at approximately $97/share, representing a 41% premium to the closing share price, which signals a strong market confidence in the deal.
Bears Say
Clinical Trial ConcernsPetosemtamab monotherapy data in a Phase 1 CRC trial showed a 0% response rate, raising concerns about its effectiveness.
Underperformance In ExpectationsThe petosemtamab+chemotherapy treatment slightly underperformed with response rates of 60-65% and 28-35% for 1L and 2L, not meeting high investor expectations.
Valuation ConcernsThe acquisition price suggests minimal valuation for petosemtamab in CRC, implying limited immediate upside from this specific asset.
Merus News
MRUS FAQ
What was Merus NV’s price range in the past 12 months?
Merus NV lowest stock price was $33.19 and its highest was $94.56 in the past 12 months.
What is Merus NV’s market cap?
Merus NV’s market cap is $7.14B.
When is Merus NV’s upcoming earnings report date?
Merus NV’s upcoming earnings report date is Oct 30, 2025 which is in 26 days.
How were Merus NV’s earnings last quarter?
Merus NV released its earnings results on Aug 05, 2025. The company reported -$2.23 earnings per share for the quarter, missing the consensus estimate of -$1.165 by -$1.065.
Is Merus NV overvalued?
According to Wall Street analysts Merus NV’s price is currently Undervalued.
Does Merus NV pay dividends?
Merus NV does not currently pay dividends.
What is Merus NV’s EPS estimate?
Merus NV’s EPS estimate is -1.37.
How many shares outstanding does Merus NV have?
Merus NV has 75,784,440 shares outstanding.
What happened to Merus NV’s price movement after its last earnings report?
Merus NV reported an EPS of -$2.23 in its last earnings report, missing expectations of -$1.165. Following the earnings report the stock price went down -2.832%.
Which hedge fund is a major shareholder of Merus NV?
Currently, no hedge funds are holding shares in MRUS
Merus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$97.07 (2.95% Upside)
$97.07 (2.95% Upside)
Blogger Sentiment
Bullish
MRUS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 742.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.21%
12-Months-Change
Fundamentals
Return on Equity
-48.54%
Trailing 12-Months
Asset Growth
9.86%
Trailing 12-Months
Company Description
Merus NV
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
MRUS Stock 12 Month Forecast
Average Price Target
$97.07
▲(2.95% Upside)
Technical Analysis
PTC Therapeutics
―
Zai Lab
―
Krystal Biotech
―
Akero Therapeutics
―
Avidity Biosciences
―
Ownership Overview
0.15% Insiders
20.54% Mutual Funds
61.09% Other Institutional Investors
16.19% Public Companies and
Individual Investors